Enrichment strategies in glycomics‐based lung cancer biomarker development

There is a need to identify better glycan biomarkers for diagnosis, early detection, and treatment monitoring in lung cancer using biofluids such as blood. Biofluids are complex mixtures of proteins dominated by a few high abundance proteins that may not have specificity for lung cancer. Therefore, two methods for protein enrichment were evaluated; affinity capturing of IgG and enrichment of medium abundance proteins, thus allowing us to determine which method yields the best candidate glycan biomarkers for lung cancer.

[1]  Kyoungmi Kim,et al.  Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses , 2013, Analytical and Bioanalytical Chemistry.

[2]  Y. Mechref,et al.  Defining putative glycan cancer biomarkers by MS. , 2012, Bioanalysis.

[3]  P. Massion,et al.  The State of Molecular Biomarkers for the Early Detection of Lung Cancer , 2012, Cancer Prevention Research.

[4]  L. McDonnell,et al.  N-glycosylation of Colorectal Cancer Tissues , 2012, Molecular & Cellular Proteomics.

[5]  J. Gu,et al.  Potential roles of N-glycosylation in cell adhesion , 2012, Glycoconjugate Journal.

[6]  M. Wuhrer.  Glycomics using mass spectrometry , 2012, Glycoconjugate Journal.

[7]  W. Alley,et al.  N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. , 2012, Journal of proteome research.

[8]  Mary Ann Comunale,et al.  Increased Levels of Tetra-antennary N-Linked Glycan but Not Core Fucosylation Are Associated with Hepatocellular Carcinoma Tissue , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[9]  A. Geerts,et al.  N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[10]  Radoslav Goldman,et al.  Semi-automated identification of N-Glycopeptides by hydrophilic interaction chromatography, nano-reverse-phase LC-MS/MS, and glycan database search. , 2012, Journal of proteome research.

[11]  A. Deelder,et al.  Hexapeptide library as a universal tool for sample preparation in protein glycosylation analysis. , 2012, Journal of proteomics.

[12]  B. Sergeyev,et al.  Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival , 2011, Glycoconjugate Journal.

[13]  N. Bohorova,et al.  Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant , 2011, Proceedings of the National Academy of Sciences.

[14]  C. Lebrilla,et al.  Application of nano-LC-based glycomics towards biomarker discovery. , 2011, Bioanalysis.

[15]  C. Lebrilla,et al.  Comprehensive native glycan profiling with isomer separation and quantitation for the discovery of cancer biomarkers. , 2011, The Analyst.

[16]  N. Hastie,et al.  High Throughput Isolation and Glycosylation Analysis of IgG–Variability and Heritability of the IgG Glycome in Three Isolated Human Populations , 2011, Molecular & Cellular Proteomics.

[17]  Jayne E. Telford,et al.  Novel glycan biomarkers for the detection of lung cancer. , 2011, Journal of proteome research.

[18]  Sylvain Julien,et al.  Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis , 2011, Breast Cancer Research.

[19]  André M Deelder,et al.  Plasma protein N-glycan profiles are associated with calendar age, familial longevity and health. , 2011, Journal of proteome research.

[20]  Yue Fan,et al.  Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. , 2011, Glycobiology.

[21]  S Hanash,et al.  Mining the plasma proteome for disease applications across seven logs of protein abundance. , 2011, Journal of proteome research.

[22]  J. Verschuuren,et al.  IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis. , 2011, Journal of proteome research.

[23]  Scott R. Kronewitter,et al.  High-Mannose Glycans are Elevated during Breast Cancer Progression* , 2010, Molecular & Cellular Proteomics.

[24]  Pauline M Rudd,et al.  Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation. , 2010, Analytical chemistry.

[25]  Scott R. Kronewitter,et al.  Human serum processing and analysis methods for rapid and reproducible N-glycan mass profiling. , 2010, Journal of proteome research.

[26]  J. Houwing-Duistermaat,et al.  Decreased Levels of Bisecting GlcNAc Glycoforms of IgG Are Associated with Human Longevity , 2010, PloS one.

[27]  N. Packer,et al.  The lectin riddle: glycoproteins fractionated from complex mixtures have similar glycomic profiles. , 2010, Omics : a journal of integrative biology.

[28]  M. Tajiri,et al.  Quantitation of saccharide compositions of O-glycans by mass spectrometry of glycopeptides and its application to rheumatoid arthritis. , 2010, Journal of proteome research.

[29]  Michael S. Bereman,et al.  The effects of abundant plasma protein depletion on global glycan profiling using NanoLC FT-ICR mass spectrometry , 2010, Analytical and bioanalytical chemistry.

[30]  Maurice H J Selman,et al.  Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study , 2009, Arthritis research & therapy.

[31]  Scott R. Kronewitter,et al.  The development of retrosynthetic glycan libraries to profile and classify the human serum N‐linked glycome , 2009, Proteomics.

[32]  K. Killeen,et al.  Profile of native N‐linked glycan structures from human serum using high performance liquid chromatography on a microfluidic chip and time‐of‐flight mass spectrometry , 2009, Proteomics.

[33]  Thomas Iskratsch,et al.  Specificity analysis of lectins and antibodies using remodeled glycoproteins. , 2009, Analytical biochemistry.

[34]  P. Righetti,et al.  The art of observing rare protein species in proteomes with peptide ligand libraries , 2009, Proteomics.

[35]  Roy Jefferis,et al.  Glycosylation as a strategy to improve antibody-based therapeutics , 2009, Nature Reviews Drug Discovery.

[36]  M. Wuhrer,et al.  Oligosaccharide analysis by graphitized carbon liquid chromatography–mass spectrometry , 2009, Analytical and bioanalytical chemistry.

[37]  André M Deelder,et al.  IgG glycosylation analysis , 2009, Proteomics.

[38]  N. Packer,et al.  Rat liver membrane glycoproteome: enrichment by phase partitioning and glycoprotein capture. , 2009, Journal of proteome research.

[39]  Pauline M Rudd,et al.  Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. , 2007, Glycobiology.

[40]  E. Gottlin,et al.  Haptoglobin and posttranslational glycan‐modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer , 2007, Cancer.

[41]  André M Deelder,et al.  Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum , 2007, Proteomics.

[42]  J. Marth,et al.  Glycosylation in Cellular Mechanisms of Health and Disease , 2006, Cell.

[43]  F. Altmann,et al.  Comprehensive glyco‐proteomic analysis of human α1‐antitrypsin and its charge isoforms , 2006, Proteomics.

[44]  W. Hancock,et al.  Approach to the comprehensive analysis of glycoproteins isolated from human serum using a multi-lectin affinity column. , 2004, Journal of chromatography. A.

[45]  N. Anderson,et al.  The Human Plasma Proteome: History, Character, and Diagnostic Prospects , 2003, Molecular & Cellular Proteomics.

[46]  R Apweiler,et al.  On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. , 1999, Biochimica et biophysica acta.

[47]  N. Packer,et al.  A general approach to desalting oligosaccharides released from glycoproteins , 1998, Glycoconjugate Journal.

[48]  T. Yasuda,et al.  Structural changes in the oligosaccharide moiety of human IgG with aging , 1998, Glycoconjugate Journal.

[49]  R. Dwek,et al.  Oligosaccharide sequencing technology , 1997, Nature.

[50]  K. Segawa,et al.  Increased expression of highly branched N-glycans at cell surface is correlated with the malignant phenotypes of mouse tumor cells. , 1997, Cancer research.

[51]  R. Jefferis,et al.  Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. , 1989, The Biochemical journal.

[52]  R. Dwek,et al.  Age-related galactosylation of the N-linked oligosaccharides of human serum IgG , 1988, The Journal of experimental medicine.

[53]  R. Dwek,et al.  GALACTOSYLATION OF IgG ASSOCIATED OLIGOSACCHARIDES: REDUCTION IN PATIENTS WITH ADULT AND JUVENILE ONSET RHEUMATOID ARTHRITIS AND RELATION TO DISEASE ACTIVITY , 1988, The Lancet.

[54]  R. Dwek,et al.  Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG , 1985, Nature.

[55]  M. Burger,et al.  Wheat germ agglutinin. Molecular characteristics and specificity for sugar binding. , 1974, The Journal of biological chemistry.

[56]  I. Goldstein,et al.  PROTEIN-CARBOHYDRATE INTERACTION. II. INHIBITION STUDIES ON THE INTERACTION OF CONCANAVALIN A WITH POLYSACCHARIDES. , 1965, Biochemistry.

[57]  J. Merrick,et al.  PROTEIN-CARBOHYDRATE INTERACTION. I. THE INTERACTION OF POLYSACCHARIDES WITH CONCANAVALIN A. , 1965, Biochimica et biophysica acta.

[58]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[59]  T. Rademacher,et al.  Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. , 1994, Human antibodies and hybridomas.

[60]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[61]  L. Opie.  Drugs and the heart. VI. Vasodilating drugs. , 1980, Lancet.